Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025)

Mira Pharmaceuticals' (MIRA) quarterly Net Income towards Common Stockholders came in at -$6.0 million in Q4 2025, down 149.34% year-on-year from $12.1 million in Q4 2024, and up 73.64% quarter-over-quarter from -$22.7 million in Q3 2025.

Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

Mira Pharmaceuticals has disclosed Net Income towards Common Stockholders across 2 years of filings, most recently posting -$6.0 million for Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$6.0 million, down 149.34% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28.7 million (down 545.38% YoY), and the FY2025 annual result was -$32.0 million, down 307.5% from the prior year.
  • Net Income towards Common Stockholders came in at -$6.0 million for Q4 2025 at Mira Pharmaceuticals, up from -$22.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.0 million in Q3 2024 to a low of -$22.7 million in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.34 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -13.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Mira Pharmaceuticals 23.69 Mn 12.66 Mn - -5.98 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -5.98 Mn
Sep 30, 2025 -22.69 Mn
Dec 31, 2024 -2.40 Mn
Sep 30, 2024 -2.04 Mn